Management of lipid disorders in the elderly

Drugs and Aging

Volumn 10, Issue 6, 1997, Pages 444-462

  Playford, David A ^a   Watts, Gerald F ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ANTIOXIDANT; ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; CIPROFIBRATE; CLOFIBRATE; COLESTIPOL; ESTROGEN; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; PROBUCOL; SIMVASTATIN; TRIACYLGLYCEROL;

AGED; AGING; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIET THERAPY; DRUG EFFICACY; DRUG FATALITY; ESTROGEN DEFICIENCY; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMPOTENCE; LIFE EXPECTANCY; LIPID METABOLISM; LIPOPROTEIN METABOLISM; OBESITY; PRIORITY JOURNAL; QUALITY OF LIFE; RESOURCE ALLOCATION; REVIEW; SKIN DISEASE; SMOKING CESSATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

EID: 0030988252     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199710060-00005     Document Type: Review

References (146)

1. National Center for Health Statistics. Vital statistics of the United States, 1989, vol. II: mortality, part A. DHHS Publication (PHS): 93-1101. Washington, DC: Government Printing Office, 1993
2. Hazzard WR. Ageing and atherosclerosis: teasing out the contributions of time, secondary ageing, and primary ageing. Clin Geriatr Med 1985; 1 (1): 251-84
3. Sullivan JL. The sex difference in ischaemic heart disease. Perspect Biol Med 1983; 26 (4): 657-71
4. Stampfer MJ, Colditz GA, Willett WC. Menopause and heart disease: a review. Ann N Y Acad Sci 1990; 592: 193-203; discussion 257-62
5. Gordon DJ, Rifkind BM. Treating high blood cholesterol in the older patient. Am J Cardiol 1989; 63 (16): 48H-52H
6. Abbott RD, Wilson PWF, Kannel WB, et al. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction: the Framingham Study. Arteriosclerosis 1988; 8: 207-11
7. Zimmelbaum P, Frishman WH, Ooi WL, et al. Plasma lipids and lipoproteins and the incidence of cardiovascular disease in the very elderly: the Bronx aging study. Arteriosclerosis 1992; 12: 416-23
8. Barrett-Connor E, Suarez L, Khaw K, et al. Ischaemic heart disease risk factors after age 50. J Chronic Dis 1984; 37 (12): 903-8
9. Kannel WB, Cobb J. Framingham study: risk factors in cohort aged 65 and older: prevention of coronary heart disease in the elderly workshop. International Task Force for Prevention of Coronary Heart Disease. London: Current Medical Literature, 1990: 3-17
10. Castelli WP. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol 1992; 70 (19): 3H-9H
11. Oliver M, Poole-Wilson P, Shepherd J, et al. Lower patients' cholesterol now: trial evidence shows clear benefits from secondary prevention. BMJ 1995; 310: 1280-1
12. Wood DA. Cholesterol lowering does have a role in secondary prevention. Br Heart J 1995; 73: 4-5
13. Swan HJC. Why cardiologists must be interested in lipids. Am J Cardiol 1995; 75: 1067-8
14. Dayton S, Pearce ML, Goldman H, et al. Controlled clinical trial of a diet high in unsaturated fat for prevention of atherosclerotic complications. Circulation 1968; 2 (57): 1060-2
15. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988; 223: 405-18
16. Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial. Am J Hypertens 1996 Apr; 9 (4 Pt 1): 342-60
17. Curb JD, Masaki K, Rodriguez BL, et al. Peripheral artery disease and cardiovascular risk factors in the elderly - the Honolulu heart program. Arterioscler Thromb Vasc Biol 1995; 15: 1495-500
18. Johnston JD, Watts GF. Lipid-lowering drugs in the management of atherosclerosis. Curr Pract Surg 1994; 6: 45-51
19. Miller NE. Aging and plasma lipoproteins. In: Hazzard WR, Andres R, Bierman EL, et al., editors. Principles of geriatric medicine and gerontology. 2nd ed. New York: McGraw-Hill. 1990: 767
20. Huttunen JK, Ehnholm C, Kekki M, et al. Post-heparin plasma lipoprotein lipase and hepatic lipase in normal subjects and in patients with hypertriglyceridaemia: correlation to sex, age and various parameters of triglyceride metabolism. Clin Sci Mol Med 1976; 50 (4): 249-60
21. Eriksson M, Berglund L, Rudling M, et al. Effects of oestrogen on low density lipoprotein metabolism in males: short-term and long-term studies during hormone treatment of prostatic carcinoma. J Clin Invest 1989; 84 (3): 802-10
22. Rudman D, Mattson DE, Nagraj HS, et al. Antecedents of death in the men of a Veterans Administration nursing home. J Am Geriatr Soc 1987; 35 (6): 496-502
23. Noel MA, Smith TK, Ettiger WH. Characteristics and outcomes of hospitalized older patients who develop hypocholesterolemia. J Am Geriatr Soc 1991; 39 (5): 455-61
24. Yaari S, Goldbourt U, Even-Zoliar S, et al. Associations of serum high density lipoprotein and total cholesterol with total, cardiovascular, and cancer mortality in a 7 year prospective study of 10,000 men. Lancet 1981; 1: 1011-5
25. Bierman EL. Atherosclerosis and ageing. Fed Proc 1978; 37 (14): 2832-6
26. Hershcopf RJ, Elahi D, Andres R, et al. Longitudinal changes in serum cholesterol in man: an epidemiological search for an aetiology. J Chronic Dis 1982; 35 (2): 101-14
27. Hurley BF, Seals DR, Hagberg JM, et al. High-density-lipoprotein cholesterol in body-builders vs powerlifters: negative effect of androgen use. JAMA 1984; 252 (4): 507-13
28. Taggart HM, Applebaum-Bowden D, Haffner S, et al. Reduction in high-density lipoproteins by anabolic steroids (stanozolol) therapy for postmenopausul osteoporosis. Metabolism 1982; 31 (11): 1147-52
29. Miller GJ. The epidemiology of plasma lipoproteins in atherosclerotic disease. In: Miller NE, Lewis B, editors. Lipoproteins, atherosclerosis and coronary heart disease. New York: Elsevier, 1981: 59
30. Miller NE. On the associations of body cholesterol pool size with age. HDL cholesterol and plasma total cholesterol concentration in humans. Atherosclerosis 1987; 67: 163-72
31. Gidez LI, Eder HA. Chapter 17: the clinical significance of plasma high-density lipoproteins. In: Miller NE, Miller GJ, editors. Clinical and metabolic aspects of high density lipoproteins. New York: Elsevier, 1984: 415
32. Puchois P, Kandoussi A, Fievet P, et al. Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis 1987; 68: 35-40
33. Cockerill GW, Rye KA, Gamble JR, et al. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995; 15: 1987-94
34. Schaefer EJ, Foster DM, Zech LA, et al. The effects of oestrogen administration on plasma lipoprotein metabolism in premenopausal females. J Clin Endocrinol Metab 1983; 57 (2): 262-7
35. Hazzard WR, Haffner SM, Kushwaha RS, et al. Preliminary report: kinetic studies on the modulation of high-density lipoprotein, apolipoprotein, and subfraction metabolism by sex steroids in a postmenopausal woman. Metabolism 1984; 33 (9): 779-84
36. Mann JI, Lewis B, Shepherd J, et al. Blood lipid concentrations and other cardiovascular risk factors: distribution, prevalence and detection in Britain. BMJ 1988; 296: 1702-6
37. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993; 269: 3015-23
38. Lipid Research Clinics Program Epidemiology Committee. Plasma lipid distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. Circulation 1979; 60 (2): 427-39
39. Reed D, Benfante R. Lipid and lipoprotein predictors of coronary heart disease in elderly men in the Honolulu Heart Program. Ann Epidemiol 1990; 2: 29-34
40. Assmann G, Schulte H. Relation of high density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 1992; 70 (7): 733-7
41. Rubin SM, Sidney S, Black DM, et al. High blood cholesterol in elderly men and the excess risk for coronary heart disease. Ann Intern Med 1990; 113 (12): 916-20
42. Fries JF, Green LW, Levine S. Health promotion and the compression of morbidity. Lancet 1989; 1: 481-3
43. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994; 344: 1383-9
44. Sacks FM, Pfeffer MA, Moye LA, et al., for the Cholesterol And Recurrent Events (CARE) trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9
45. Pfeffer MA, Sacks FM, Moye LA, et al., for the Cholesterol And Recurrent Events (CARE) trial investigators. Cholesterol and recurrent events: a secondary prevention trial for normolipidemic patients. Am J Cardiol 1995; 76 (9): 98C-106C
46. Canner PL, Berge KG, Wenger NK, et al. The coronary drug project. J Am Coll Cardiol 1986; 8: 1245-55
47. Lipid Research Clinics Program. The research clinics coronary primary prevention trial results II. JAMA 1984; 251: 365-74
48. Shepherd J, Cobbe SM, Ford I, et al., for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995; 333: 1301-7
49. Frick MH, Elo O, Haapa K, et al. Helsinki heart study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidaemia. N Engl J Med 1987; 317: 1237-45
50. Hazzard WR. Dyslipoproteinaemia in the elderly: should it be treated? Clin Geriatr Med 1992; 8 (1): 89-102
51. Watts GF. Lipid-lowering therapy and regression of atherosclerosis. Endocrinol Metab 1994; 1: 71-87
52. Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257: 3233-40
53. Ericsson C-G, Hamsten A, Nilsson J, et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996; 347: 849-53
54. Jukema JW, Bruschke VG, van Boven AJ, et al., on behalf of the REGRESS Study Group. Effect of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the regression growth evaluation statin study (REGRESS). Circulation 1995; 91: 2528-40
55. Pitt B, Mancini GBJ, Ellis SG, et al., for the PLAC I Investigators. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC 1): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol 1995; 26: 1133-9
56. Brown BG, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of aggressive lipid lowering in men with high levels of apolipoprotein B: the Familial Atherosclerosis Treatment Study (FATS). N Engl J Med 1990; 323: 1289-98
57. Salonen R, Nyyssönen K, Porkkala E, et al. KAPS: a population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995; 92: 1758-64
58. Furberg CD, Adams Jr HP, Applegate WB, et al., for the Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994; 90: 1679-87
59. Crouse JR, Byington RP, Bond MG, et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC II). Am J Cardiol 1995; 75: 455-9
60. Hodis HN, Mack WJ, LaBree L, et al. Reduction in carotid wall thickness using lovastatin and dietary therapy: a randomized, controlled clinical trial. Ann Intern Med 1996; 124: 548-56
61. Blankenhorn DH, Azen SP, Kramsch DM, et al., for the MARS group. Coronary angiographic changes with lovastatin therapy: the monitored atherosclerosis regression study (MARS). Ann Intern Med 1993; 119: 969-76
62. Marmot MG, Poulter NR. Primary prevention of stroke. Lancet 1992; 339: 344-7
63. Duffield RG, Lewis B, Miller NE, et al. Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis: a randomised controlled trial. Lancet 1983; 11 (8351): 639-42
64. Ischaemic heart disease: a secondary prevention trial using clofibrate. Report by a research committee of the Scottish Society of Physicians. BMJ 1971; 790 (4): 775-84
65. Trial of clofibrate in the treatment of ischaemic heart disease: five-year study by a group of physicians of the Newcastle upon Tyne region. BMJ 1971; 790 (4): 767-75
66. Miettinen M, Turpeinen O, Karvonen MJ, et al. Effect of cholesterol-lowering diet on mortality from coronary heart-disease and other causes: a twelve year clinical trial in men and women. Lancet 1972; 11: 835-8
67. LaRosa JC, Applegate W, Crouse III JR, et al. Cholesterol Reduction in Seniors Program (CRISP) pilot study. Arch Intern Med 1994; 154: 529-39
68. Thompson GR, Hollyer J, Waters DD. Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease. Curr Opin Lipidol 1995; 6: 386-8
69. Watts GF, Burke V, Lewis B. Plasma LDL cholesterol levels and progression of coronary artery disease: a metaregression analysis of angiographic trials. Br J Cardiol. In press
70. Vandenbroucke JP, Westerdorp RGJ. Are the effects of cholesterol lowering drugs always equal? Lancet 1996; 347: 1267-8
71. Campeau L, Knatterud GL, Domanski M, et al., for the Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997; 336: 153-62
72. LaRosa JC. Dyslipoproteinaemia in women and the elderly. Med Clin North Am 1994 Jan; 78 (1): 163-79
73. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and low density lipoprotein cholesterol and high density lipoprotein cholesterol concentration on coronary heart disease risk in the Helsinki heart study: implications for treatment. Circulation 1992; 85: 37-45
74. Fuller JH, Shipley MJ, Rose G, et al. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study. Br Med J (Clin Res Ed) 1983; 287: 867-70
75. Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiological view. Diabetes Metab Rev 1987; 3: 463-524
76. Krolewski AS, Warram JF, Valsania P, et al. Evolving natural history of coronary artery disease in diabetes mellitus. Am J Med 1991; 90 Suppl. 2A: 56S-61S
77. Cohen RA. Dysfunction of vascular endothelium in diabetes mellitus. Circulation 1993; 87 Suppl. V: V67-76
78. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43: 109-216
79. Flavahan NA. Atherosclerosis or lipoprotein-induced endothelial dysfunction. Circulation 1992; 85: 1927-38
80. Hsueh WA, Anderson PW. Hypertension, the endothelial cells and the vascular complications of diabetes mellitus. Hypertension 1992; 20: 253-63
81. Jaap AJ, Tooke JE. Pathophysiology of microvascular disease in NIDDM. Clin Sci 1995; 89: 3-12
82. Nitenberg A, Valensi P, Sacks R, et al. Impairment of coronary vascular reserve and ACh-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function. Diabetes 1993; 42: 1017-25
83. Despres JP. Abdominal obesity as an important component of insulin-resistance syndrome. Nutrition 1993; 9 (5): 452-9
84. Brownell KD, Stunkard AJ. Differential changes in plasma high-density lipoprotein-cholesterol levels in obese men and women during weight reduction. Arch Intern Med 1981; 141 (9): 1142-6
85. Colditz GA, Willett WC, Stampfer MJ, et al. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987; 316: 1105-10
86. Barrett-Connor E, Bush TL. Oestrogen and coronary heart disease in women. JAMA 1991; 265 (14): 1861-7
87. American College of Physicians. Guidelines for counselling postmenopausal women about preventive hormone therapy. Ann Intern Med 1992; 117: 1038-41
88. Guetta V, Cannon RO. Cardiovascular effects of oestrogen and lipid-lowering therapies in postmenopausal women. Circulation 1996; 93: 1928-37
89. Grodstein F, Stampfer MJ, Manson MD, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453-61
90. Hunt K, Vessey M, McPherson K, et al. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 1987; 94: 620-35
91. Falkeborn M, Persson I, Adami H-O, et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 1992; 99: 821-8
92. Psaty BM, Heckbert SR, Atkins D, et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994; 154: 1333-9
93. Miller VM, Vanhoutte PM. Progesterone and modulation of endothelium-dependent responses in canine coronary arteries. Am J Physiol 1991; 261 (4 Pt 2): R1022-7
94. Williams JK, Honore EK, Washburn SA, et al. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. Am J Coll Cardiol 1994; 24: 1757-61
95. Dietary guidelines for Australians. National Health and Medical Research Council, 1992. Better Printing Service (NSW): 21-2
96. Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? The lifestyle heart trial. Lancet 1990; 336: 129-33
97. Watts GF, Lewis B, Brunt JNH, et al. Effects on coronary artery disease of lipid lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992; 339: 563-9
98. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992 Jun 20; 339: 1523-6
99. Gronbaek M, Sorensen TI. Alcohol consumption and risk of coronary heart disease: studies suggest that wine has additional effect to that of ethanol [letter]. BMJ 1996 Aug 10; 313: 365
100. White IR. The cardioprotective effects of moderate alcohol consumption [editorial]. BMJ 1996 May 11; 312: 1179-80
101. Rimm EB, Klatsky A, Grobbee D, et al. Review of moderate alcohol consumption and reduced risk of coronary heart disease: is the effect due to beer, wine, or spirits? BMJ Mar 23; 312: 731-6
102. Dietschy JM. In: Bates S, Gangloff E, editors. Atherosclerosis and ageing. New York: Springer-Verlag, 1987: 104
103. Grundy SM, Denke MA. Dietary influences on serum lipids and lipoproteins. J Lipid Res 1990; 31 (7): 1149-72
104. Hennekens CH, Gaziano JM, Manson JE, et al. Antioxidant vitamin-cardiovascular disease hypothesis is still promising, but still unproven: the need for randomised trials. Am J Clin Nutr 1995; 62 Suppl.: 1377S-80S
105. Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS) [comment]. Lancet 1996; 347: 775-7
106. Steinberg D. Clinical trials of antioxidants in atherosclerosis: are we doing the right thing? Lancet 1995; 346: 36-8
107. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish and fibre intake on death and myocardial infarction: Diet And Reinfarction Trial (DART). Lancet 1989; 11: 757-61
108. Temple NJ. Dietary fats and coronary heart disease. Biomed Pharmacother 1996; 50: 261-8
109. Stone NJ. Fish consumption, fish oil, lipids and coronary heart disease. Circulation 1996; 94 (9): 2337-40
110. Harris WS. Dietary fish oil and blood lipids. Curr Opin Lipidol 1996; 7 (1): 3-7
111. Heemskerk JW, Vossen RC, van Dam Mieras MC. Polyunsaturated fatty acids and function of platelets and endothelial cells. Curr Opin Lipidol 1996; 7 (1): 24-9
112. Sanders TA. Effects of unsaturated fatty acids on blood clotting and fibrinolysis. Curr Opin Lipidol 1996; 7 (1): 20-3
113. Schaefer EJ, Lichtenstein AH, Lamon Fava S, et al. Effects of National Cholesterol Education Program Step 2 diets relatively high or relatively low in fish-derived fatty acids on plasma lipoproteins in middle-aged and elderly subjects. Am J Clin Nutr 1996 Feb; 63 (2): 234-41
114. Kromhout D, Feskens EJ, Bowles CH. The protective effect of a small amount of fish on coronary heart disease mortality in an elderly population. Int J Epidemiol 1995 Apr; 24 (2): 340-5
115. Shear CL, Franklin FA, Stinnett S, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins. Circulation 1992; 85 (4): 1293-303
116. Boccuzzi SJ, Bocanegra TS, Walker JF, et al. Long-term safety and efficacy profile of simvastatin. Am J Cardiol 1991; 68 (11): 1127-31
117. Farmer JA, Gotto Jr AM. Antihyperlipidaemic agents: drug interactions of clinical significance. Drug Saf 1994; 11 (5): 301-9
118. Illingworth DR. Drug therapy of hypercholesterolaemia. Clin Chem 1988; 34 (8B): B123-32
119. Lacoste L, Lam JYT, Hung J, et al. Hyperlipidaemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995; 92: 3172-7
120. Brown WV. Review of clinical trials: proving the lipid hypothesis. Eur Heart J 1990; 11 Suppl. H: 15-20
121. Hughes AD. The role of isoprenoids in vascular smooth muscle: potential benefits of statins unrelated to cholesterol lowering. J Hum Hypertens 1996; 10 (6): 387-90
122. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996 Oct 19; 348: 1079-82
123. Hsu I, Spinler SA, Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolaemia. Ann Pharmacother 1995 Jul-Aug; 29 (7-8): 743-59
124. The Simvastatin Pravastatin Study Group. Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolaemia. Am J Cardiol 1993 Jun 15; 71 (16): 1408-14
125. Garnett WR. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health-Syst Pharm 1995 Aug 1; 52 (15): 1639-45
126. Rossouw JE, Santello NC, Heyse JF, et al. Cholesterol reduction yields clinical benefit: a new look at old data. Circulation 1995; 91: 2274-82
127. Feher MD, Foxton J, Banks D, et al. Long term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary heart disease. Br Heart J 1995; 74 (1): 14-7
128. Tenkanen L, Pietila K, Manninen V, et al. The triglyceride issue revisited: findings from the Helsinki Heart Study. Arch Intern Med 1994 Dec 12-26; 154 (23): 2714-20
129. Bunte T, Haliman HW, Hellwig N, et al. Effects of fenofibrate on angiographically examined coronary atherosclerosis and left ventricular function in hypercholesterolaemic patients. Atherosclerosis 1993; 98: 127-38
130. Olsson AG, Rubin G, Erikson U. The effect of serum lipid regulation on the development of femoral atherosclerosis in hyperlipidaemia: a non-randomised control study. J Intern Med 1990; 227: 381-90
131. Lipid Research Clinics Program. The Lipid Research clinics coronary primary prevention trial results I: reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-64
132. Walldius G, Erikson U, Olsson AG, et al. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1994; 74: 875-83
133. Crouse III JR. New developments in the use of niacin for treatment of hyperlipidaemia: new considerations in the use of an old drug. Coron Artery Dis 1996; 7 (4): 321-6
134. Blankenborn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257: 3233-40
135. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: long term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245-55
136. Hodis HN, Mack WJ, LaBree L, et al. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. JAMA 1995; 273: 1849-54
137. Bellizzi MC, Franklin MF, Duthie CG, et al. Vitamin E and coronary heart disease: the European paradox [published erratum appears in Eur J Clin Nutr 1995 Mar; 49 (3): 230]. Eur J Clin Nutr 1994 Nov; 48 (11): 822-31
138. Kushi LH, Folsom AR, Prineas RJ, et al. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med 1996 May 2; 334 (18): 1156-62
139. Hennekens CH, Gaziano JM, Manson JE, et al. Antioxidant vitamin-cardiovascular disease hypothesis is still promising, but still unproven: the need for randomized trials. Am J Clin Nutr 1995 Dec; 62 (6 Suppl.): 1377S-80S
140. Singh RB, Niaz MA, Bishnoi I, et al. Diet, antioxidant vitamins, oxidative stress and risk of coronary artery disease: the Peerzada Prospective Study. Acta Cardiol 1994; 49 (5): 453-67
141. Levy Y, Nseir W, Boulos M, et al. Relationship between plasma antioxidants and coronary artery disease [in Hebrew]. Harefuah 1994 Sep; 127 (5-6): 154-7, 216, 215
142. Yusuf S, Anand S. Cost of prevention: the case of lipid lowering. Circulation 1996; 93: 1774-6
143. Reckless JPD. Cost-effectiveness of clinical care for hyperlipidaemia. In: Lewis B, Assmann G, editors. The social and economic contexts of coronary prevention. London: Current Medical Literature, 1990: 94-108
144. Oster G, Thompson D. Estimated effects of reducing dietary saturate fat intake on the incidence and costs of coronary heart disease in the United States. J Am Diet Assoc 1996; 96: 127-31
145. Meyers DG. Relative survival benefits of risk factor modification. Am J Cardiol 1996; 77: 298-9
146. Fries J. Ageing, natural death, and the compression of morbidity. N Engl J Med 1980; 303 (3): 130-5